Similar articles

• Global "hold-em".

  Cassidy BS. Cassidy BS. Geriatr Nurs. 2006 Jan-Feb;27(1):21-3. doi: 10.1016/j.gerinurse.2005.09.012. Geriatr Nurs. 2006. PMID: 16483897 No abstract available.
• The Health Impact Fund: incentives for improving access to medicines.

  Banerjee A, Hollis A, Pogge T. Banerjee A, et al. Lancet. 2010 Jan 9;375(9709):166-9. doi: 10.1016/S0140-6736(09)61296-4. Lancet. 2010. PMID: 20109894 No abstract available.
• Global access to quality-assured medical products: the Oxford Statement and call to action.

  Newton PN, Bond KC; Oxford Statement signatories. Newton PN, et al. Lancet Glob Health. 2019 Dec;7(12):e1609-e1611. doi: 10.1016/S2214-109X(19)30426-7. Lancet Glob Health. 2019. PMID: 31708137 No abstract available.
• Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.

  Nsimba SE. Nsimba SE. East Afr J Public Health. 2008 Dec;5(3):205-10. doi: 10.4314/eajph.v5i3.39004. East Afr J Public Health. 2008. PMID: 19374325 Review.
• The concept of essential medicines: lessons for rich countries.

  Hogerzeil HV. Hogerzeil HV. BMJ. 2004 Nov 13;329(7475):1169-72. doi: 10.1136/bmj.329.7475.1169. BMJ. 2004. PMID: 15539676 Free PMC article. Review.